Introduction
Various chemiluminescence (CL) reactions have been applied to various types of analysis systems, including flow-injection analysis, high performance liquid chromatography, and capillary electrophoresis. [1] [2] [3] Peroxyoxalate CL reaction is one of the most attractive reactions for CL detection in the analysis systems, because coexisting fluorescence compounds emit strong CL through the energy transfer from peroxide immediate that is generated by the reaction between oxalate reagent and hydrogen peroxide (H2O2).
That is, many fluorescence compounds and fluorescence-labeling reagents that have been synthesized so far are easily introduced to the peroxyoxalate CL using oxalate reagent and H2O2. Furthermore, it is reported that the CL detection using peroxyoxalate reaction can determine fluorescence compounds ca. 10 or 100-times as sensitive as the fluorescence detection using a normal xenon lamp. 4, 5 Our previous paper reported that the CL reaction of isoluminol isothiocyanate (ILITC) (as a chemiluminescence reagent for labeling)-microperoxidase (as a catalyst)-H2O2 (as an oxidant) had been adopted for the immune microanalysis system. 6 In this study, we tried to introduce peroxyoxalate CL that exhibits the wide possibilities mentioned above into the immune microanalysis system. Oxalate reagents must be dissolved with organic solvents. Organic solvents and H2O2 are not usually put in micro-channels in electrophoretical systems. They often cause problems concerning conductivity and bubble formation in the micro-channels in electrophoresis. Here, oxalate reagent, bis[4-nitro-2-(3,6,9-trioxadecyloxycarbonyl)phenyl]oxalate (TDPO), was dissolved with acetonitrile together with H2O2 and the mixture was put in one of the reservoirs in a microchip. The fluorescein isothiocianate (FITC)-labeled sample eluted from the micro-channel mixed with the mixture of TDPO-H2O2 to successfully produce CL. The system described here was capable of determining, with high selectivity and sensitivity, human serum albumin (HSA) or immunosuppressive acidic protein (IAP) as a cancer marker in human serum. Although, for the moment, the detection limit in the present system was almost the same as the previous system using ILITC CL reaction, 6 the introduction of peroxyoxalate CL into the immune microanalysis system enables one to use various types of fluorescence-labeling reagents, leading to the possibility of making the system more sensitive in the future.
Experimental

Reagents
All reagents used were commercially available and of analytical grade. Ion-exchanged water was distilled for use. Human serum albumin (HSA; MW, 66000) and rabbit antihuman serum lgG (anti-HSA; MW, 150000) were purchased from Sigma Chemical Co. and Wako Pure Chemical Industries, Ltd., respectively. Control human serum, immunosuppressive acidic protein (IAP; MW, 50000) and goat anti-human serum IAP (anti-IAP) were purchased from Sanko Junyaku Co., Ltd. TDPO and FITC were purchased from Wako Pure Chemical Industries, Ltd. and Tokyo Chemical Industry Co., respectively.
Labeling procedure
Labeling using FITC was carried out in the usual ways. A known amount of protein (micro-mole order) was added together with FITC to a microvessel and dissolved in 1000 μL
We developed an immune microanalysis system incorporating chemiluminescence detection, where the peroxyoxalate chemiluminescence (CL) detection using bis[4-nitro-2-(3,6,9-trioxadecyloxycarbonyl)phenyl]oxalate (TDPO)-hydrogen peroxide (H2O2)-fluorescein isothiocianate (FITC) reaction was newly adopted. The analysis system performed the following three processes on a microchip: immune reaction for high selectivity, electrophoresis for formation and transportation of the sample plug, and CL detection. The immune reaction was carried out using an antibodyimmobilized glass bead. The glass bead was placed in one of the reservoirs in the microchip along with antigen (analyte) and a known amount of FITC-labeled antigen to set up a competitive immune reaction. The reactant after the immune reaction was fed electrophoretically into the intersection, resulting in a sample plug. The sample plug was then moved into another reservoir containing TDPO-H2O2 acetonitrile solution. At this point, CL detection was performed. The system described here was capable of determining human serum albumin or immunosuppressive acidic protein as a cancer marker in human serum. of a mixture of water and triethylamine (95:5). The solution was subjected to ultrasonication for 1 min and then mixed in the dark for 20 min using a vortex mixer. The residue obtained by evaporation from the solution was redissolved in 10 mM phosphate buffer (pH 7.3) to yield FITC-labeled protein solution and FITC. For further purification to remove excess FITC, the FITC-labeled protein solution obtained as described above was subjected to column separation (PD-10 desalting columns, Amersham Pharmacia Biotech). FITC and FITClabeled protein were separated on a separation column with 10 mM phosphate buffer (pH 7.0). The fractions containing FITClabeled protein were collected to yield pure FITC-labeled protein solution containing no free FITC.
Preparation of antibody-immobilized glass beads 6
The surface of the glass beads was activated by holding 1 g of glass beads (1 mm in diameter) at 100˚C for 6 h in 50 wt% sodium hydroxide solution (5 mL). The glass beads were washed and dried well. Alkylamino-bonded glass beads were then prepared by holding them for 6 h under reflux in 2 wt% (3-aminopropyl)triethoxysilane-toluene solution (15 mL). The immobilization of anti-HSA onto alkylamino-bonded glass beads was performed by the glutaraldehyde method as follows. The glass beads were dipped in 5 wt% glutaraldehyde-ethanol solution (2.5 mL), and the mixture was allowed to react for 24 h at room temperature. After washing with 10 mM phosphate buffer (pH 7.3), the beads were dipped in 2 mL of 12 g L -1 sodium cyanoborohydride in ethanol for 5 h. After washing with phosphate buffer, the activated glass beads were dipped in 5 g L -1 antibody phosphate buffer (2 mL) and the mixture was then held at 4˚C for 48 h. The beads were dipped in 12 g L -1 sodium borohydride solution at 4˚C for 5 h. The antibodyimmobilized glass beads were then stored at 4˚C in phosphate buffer.
Microchip
A schematic layout of a microchip (12.5 × 35.0 mm) (Type U, Shimadzu Corp.) is shown in Fig. 1 . The microchips made of quartz consisted of sample load and separation micro-channels 20 μm deep and 50 μm wide, as well as holes 2.0 mm in diameter drilled into the chip to facilitate access to the micro-channels and to serve as reservoirs (R1 -R4 in Fig. 1 ). The channel length from the intersection to R4, which corresponds to the effective separation length, was 31.0 mm. The photomultiplier tube (R7400U, Hamamatsu Co.) was located under R4.
Analytical procedure and apparatus
The reaction of TDPO and H2O2 was used in conjunction with FITC as a fluorescence compound. Phosphate buffer (10 mM, pH 7.3) was used as the migration buffer. Acetonitrile solution (CL solution) containing 4 mM TDPO and 0.6 wt% H2O2 was added to the detection cell (R4). After the channels were filled with migration buffer using a disposable syringe, the sample was placed in R1, with migration buffer in R2 and R3, and CL solution in R4.
The system developed in the present study comprised the following three processes on a microchip: immune reaction for high selectivity, electrophoresis for formation and transportation of the sample plug, and CL detection for high sensitivity. Electrophoresis on the microchip was performed using a modified microchip electrophoresis system (MCE-2010, Shimadzu Co.). CL detection was performed using a modified CL detector (CLD-10A, Shimadzu Co.). Competitive immunoassay. Solutions of FITC-labeled HSA (2.0 × 10 -7 M; 10 μL) and analyte (various concentrations of HSA; 10 μL) were mixed, and an aliquot (3 μL) of the mixture then added to R1 for the competitive immune reaction against immobilized anti-HSA on the glass beads. Immediately, the reactant (sample) in R1 was delivered electrophoretically toward the intersection point to form a sample plug. Electrophoresis. Sample plug formation was achieved simply using a cross-shaped injector as follows. The sample was delivered electrokinetically from R1 toward R2 by applying 0.3 kV for 30 s to R1, with R2 held at ground. During this process, the sample stream was pinched with 0.20 and 0.28 kV applied to R3 and R4, respectively, to prevent sample spreading out to the separation channel, as the reagent in R4 may leak slightly into the separation channel due to electroosmotic flow. After the intersection was filled completely with the sample, 0.50 kV was applied to R3, with R4 grounded, allowing the sample to inject into and migrate down the separation channel. Simultaneously, 0.34 kV was applied to R1 and R2 during separation to hinder leakage of the sample into the separation channel. Any reagent that had leaked into the separation channel during sample loading was returned easily to R4 during separation. This injection technique made it possible to introduce a known and small amount of sample (of the order of several tens pL). CL detection. The sample, which migrated toward R4, came into contact with the CL reagent to produce visible light at the interface between the separation channel and R4. The light was detected with the photomultiplier tube located under R4.
Results and Discussion
Sample loading time We examined the relationship between sample loading time and CL intensity. A 2 × 10 -6 M solution of FITC-labeled HSA was placed in R1 and analyzed using the system without going through the immune reaction process. The CL intensities due to FITC-labeled HSA increased with increasing loading time up to ∼30 s, subsequently remaining almost constant, indicating that the 30 s loading time filled the intersection with FITC-labeled HSA sample. Consequently, all of the experiments in the present study were performed using a 30 s sample loading time.
Analysis of FITC-labeled HSA
Thus, FITC-labeled HSA containing no FITC, which was obtained through further purification by column separation, was used for the present system. First, FITC-labeled HSA was analyzed in a similar way using a microchip with CL detection without the immune reaction process. FITC-labeled HSA was detected within 2 min and determined over the range of 1.0 × 10 -7 -5.0 × 10 -6 M with a detection limit of 1.0 × 10 -7 M (S/N = 3).
Competitive immune reaction
Adsorption of protein to the surface of untreated glass beads was examined as follows: 2.0 × 10 -6 M FITC-labeled HSA was loaded into R1 together with untreated glass beads. The experiment was performed according to the analytical procedure described in the experimental section. The obtained CL intensity of FITC-labeled HSA was compared with that obtained without the glass beads. No difference was observed in CL intensity with and without the glass beads. Thus, the adsorption of protein onto the bare surface of the glass beads was negligible in the present study.
Detecting the non-bound fraction of labeled reagent in the competitive immunoassay leads to successful determination of analyte under conditions with no non-specific adsorption onto the immobilized antibody. The present system including immune reaction, electrophoresis, and CL detection was tested using HSA and an anti-HSA immobilized glass beads as a model antigen and antibody reaction, as well as FITC-labeled HSA.
HSA (analyte) was determined over the range of 1.0 × 10 -7 -5.0 × 10 -6 M with a detection limit of 1.0 × 10 -7 M (S/N = 3) (correlation coefficient, 0.999) through immune reaction, electrophoresis, and CL detection on a microchip. One analysis was performed within 2 min. To determine the amount of HSA in a serum sample by the present method, a control serum solution, diluted 1:2000 by volume, was added to R1 together with 2.0 × 10 -7 M ILITC-labeled HSA. The serum sample was analyzed using the system including immunoassay, electrophoresis, and CL detection. The amount of HSA in the serum was calculated using the CL intensity of labeled HSA and calibration curve of HSA. The value of HSA obtained by the present method, 3.6 g dL -1 (the average value of 6 analyses), corresponded closely to that reported by the manufacturer (3.0 -3.6 g dL -1 ). Thus, the present method is applicable to the determination of protein in serum samples.
Analysis of IAP in serum
A number of cancer markers have been identified to date. IAP is one of the most useful of these cancer markers, 7, 8 and the concentration of IAP in the blood has been shown to be increased in cancer patients. We obtained a calibration curve of IAP (analyte) using the system by use of an anti-IAPimmobilized glass bead and FITC-labeled IAP (1.0 × 10 -6 M). IAP was analyzed by immune reaction, electrophoresis, and CL detection on the microchip. As shown in Fig. 2, IAP was determined over the range of 1.0 × 10 -7 -5.0 × 10 -6 M with a detection limit of 1.0 × 10 -7 M (S/N = 3). But the assay showed good linearity over just a narrow dynamic range (1.0 × 10 -7 -2.0 × 10 -6 ). Each plot in Fig. 2 is the average of 7 -10 measurements. One analysis was performed within 2 min. To determine the amount of IAP in a serum sample by the present method, a control serum solution, diluted 1:50 by volume, was added to R1 together with 1.0 × 10 -6 M FITC-labeled IAP. The serum in R1 was analyzed using the system. The amount of IAP in the serum obtained by the present method, 310 mg dL -1 (average value of 6 analyses), also corresponded closely to that reported by the manufacturer (299 mg dL -1 ). Thus, the present method was applicable to the determination of specific protein in a serum sample.
In this study, we tried to introduce peroxyoxalate CL detection into the immune microanalysis system. The present system was applicable to the determination of specific protein, such as a cancer marker, in a serum sample. Although the detection limits in the present system were almost the same as the previous system using ILITC CL detection, 6 the introduction of peroxyoxalate CL into the immune microanalysis system enables one to use various types of fluorescence-labeling reagents, leading to the possibility of making the system more sensitive in the future. Peak area /mVs Fig. 2 The calibration curve of IAP using the immune microanalysis system. Conditions: R1, various concentrations of IAP, 1.0 × 10 -6 M FITC-labeled IAP, and anti-IAP immobilized glass bead in 10 mM phosphate buffer (pH 7.3); R2 and R3, 10 mM phosphate buffer (pH 7.3); R4, 4 mM TDPO and 0.6 wt% H2O2 acetonitrile solution.
